RecruitingNot Applicable

Safty and Efficacy of MCI Network Guided TMS for Early Alzheimer's Disease: A Randomized, Double-blind Trial

China40 participantsStarted 2025-07-20

Plain-language summary

Estimate the safty and efficacy of personalized network neuronavigated transcranial magnetic stimulations in early Alzheimer's disease patients

Age range45 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Subject diagnosed as either mild cognitive impairment due to AD or mild AD dementia based on National Institute on Aging-Alzheimer's Association criteria.
✓. MMSE score 18-28.
✓. CDR score 0.5-1.
✓. On stable treatment with IAChE or memantine for at least 6 months.
✓. Literate in Han Chinese.

✕. Recevied rTMS treatment in the past 3 months.
✕. Depression or other psychiatric disorders.
✕. History of head injury, stroke, epilepsy or other neurologic disease.
✕. Organic brain defects on T1 or T2 images.
✕. History of unexplained loss of consciousness.
✕. Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, or any implanted medical device that is incompatible with MRI.
✕. Family history of medication refractory epilepsy.
✕. History of substance abuse within the last 6 months.

Alzheimers Disease Assessment Scale Cognitive section (ADAS-Cog)

Timeframe: Baseline and 2 weeks

NCT IDNCT07138677

SponsorAnhui Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-30

Kai Wang, PhD